<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 19 Nov 2026 19:52:41 -0500--><rss version="2.0">
    <channel>
        <title>OS Therapies, Inc. (OSTX) Press Releases</title>
        <link>https://ir.ostherapies.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/ostherapies/files/theme/images/logo-sm-2x.png</url>
                <title>OS Therapies, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/137/os-therapies-announces-shelving-of-u-s-fda-commissioners</link>
                <pubDate>Fri, 13 Nov 26 08:30:00 -0500</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/137/os-therapies-announces-shelving-of-u-s-fda-commissioners</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/136/os-therapies-initiates-u-k-mhra-conditional-marketing</link>
                <pubDate>Tue, 10 Nov 26 08:15:00 -0500</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/136/os-therapies-initiates-u-k-mhra-conditional-marketing</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/135/os-therapies-completes-requalification-of-phase-2b</link>
                <pubDate>Thu, 05 Nov 26 08:00:00 -0500</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/135/os-therapies-completes-requalification-of-phase-2b</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/134/os-therapies-announces-initial-closing-of-warrant-exercise</link>
                <pubDate>Mon, 19 Oct 26 08:30:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/134/os-therapies-announces-initial-closing-of-warrant-exercise</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/133/os-animal-health-receives-usda-feedback-on-regulatory</link>
                <pubDate>Wed, 07 Oct 26 08:30:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/133/os-animal-health-receives-usda-feedback-on-regulatory</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/132/os-therapies-achieves-statistically-significant-final</link>
                <pubDate>Tue, 06 Oct 26 08:30:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/132/os-therapies-achieves-statistically-significant-final</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/131/os-therapies-appoints-kerry-clem-as-chief-commercial</link>
                <pubDate>Thu, 01 Oct 26 08:30:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/131/os-therapies-appoints-kerry-clem-as-chief-commercial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/130/os-therapies-announces-brand-name-herlystic-approved-by</link>
                <pubDate>Thu, 24 Sep 26 08:22:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/130/os-therapies-announces-brand-name-herlystic-approved-by</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/129/os-therapies-completes-fda-type-c-statistical-methods</link>
                <pubDate>Mon, 21 Sep 26 06:30:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/129/os-therapies-completes-fda-type-c-statistical-methods</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and</link>
                <pubDate>Thu, 17 Sep 26 06:00:00 -0400</pubDate>
                <guid>https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and</guid>
                                                                            </item>
            </channel>
</rss>